Literature DB >> 20817235

Portal vein embolization induces more liver regeneration than portal vein ligation in a standardized rabbit model.

Jacomina W van den Esschert1, Krijn P van Lienden, Wilmar de Graaf, Martinus A W Maas, Joris J T H Roelofs, Michal Heger, Thomas M van Gulik.   

Abstract

BACKGROUND: Portal vein ligation (PVL) and portal vein embolization (PVE) are used to induce hypertrophy of the future remnant liver before major liver resection. The aim of our study was to compare the hypertrophy response of the liver after PVL versus PVE in a rabbit model.
METHODS: Twenty rabbits were divided into an embolization group (n = 10) and a ligation group (n = 10). Both groups were divided in 2 subgroups of 5 rabbits that were humanely killed after days 7 and 14. The portal vein branches to the 3 cranial liver lobes (80% of the liver) were occluded. Regeneration of the caudal liver lobe was measured using volumetry based on computed tomography on days 3, 7, 10, and 14. Immunohistochemistry for Ki-67 and RAM11 was performed to quantify proliferating cells and macrophages. In addition, tissue tumor necrosis factor-α and interleukin-6 were assessed.
RESULTS: The caudal liver volume increased over time in both groups (P < .001), but this increase was greater after PVE than after PVL (P = .001) with a mean degree of hypertrophy of 15% ± 4% and 20% ± 2%, respectively. When comparing the groups on the separate time points, a difference was found on days 10 and 14 (P = .008 and P = .016, respectively). These data were confirmed by Ki-67 staining, which showed a greater number of proliferating hepatocytes on day 7 after embolization (P = .016). Cytokine analysis of liver tissue did not show significant differences between the ligation and embolization groups on days 7 and 14.
CONCLUSION: PVE is superior to PVL in terms of the extent of the hypertrophy response in this rabbit model.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20817235     DOI: 10.1016/j.surg.2010.07.045

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

Review 1.  Portal vein embolization before liver resection: a systematic review.

Authors:  K P van Lienden; J W van den Esschert; W de Graaf; S Bipat; J S Lameris; T M van Gulik; O M van Delden
Journal:  Cardiovasc Intervent Radiol       Date:  2012-07-18       Impact factor: 2.740

Review 2.  [Contralateral hepatic hypertrophy following unilateral yttrium-90 radioembolization : Implications for liver surgery].

Authors:  B Garlipp; M Seidensticker; D Jechorek; H Ptok; C J Bruns; J Ricke
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

3.  Relationship of immunonutritional factor with changes in liver volume after portal vein embolization.

Authors:  Atsushi Nanashima; Yukinori Tanoue; Koichi Yano; Masahide Hiyoshi; Naoya Imamura; Takeomi Hamada; Kengo Kai; Eiji Kitamura; Yasuto Suzuki; Kousei Tahira; Fumiya Kawano; Takeshi Nagayasu
Journal:  Surg Open Sci       Date:  2022-05-28

Review 4.  Tumour progression and liver regeneration--insights from animal models.

Authors:  Chetana Lim; Francois Cauchy; Daniel Azoulay; Olivier Farges; Maxime Ronot; Marc Pocard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-04-09       Impact factor: 46.802

5.  Accurate quantitation of Ki67-positive proliferating hepatocytes in rabbit liver by a multicolor immunohistochemical (IHC) approach analyzed with automated tissue and cell segmentation software.

Authors:  Chris M van der Loos; Onno J de Boer; Claire Mackaaij; Lisette T Hoekstra; Thomas M van Gulik; Joanne Verheij
Journal:  J Histochem Cytochem       Date:  2012-09-01       Impact factor: 2.479

6.  Assessment of remnant liver function and volume after selective ligation of portal vein and hepatic artery in a rat model.

Authors:  Thiago Boechat de Abreu; Alexandre de Abreu Ribeiro; Lívia Paola Colchete Provenzano; Joaquim Ribeiro Filho; Alberto Schanaider
Journal:  Acta Cir Bras       Date:  2020-01-10       Impact factor: 1.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.